Thats really exciting data: Anti-PD1 infusion in the morning associated with 50% risk reduction for both PFS & OS compared to infusion in the afternoon!

This highlights that the circadian immune rhythm has a substantial impact on antitumor immune response!

We need prospective…

Science needs more pro & con sections, more official letters and responses to articles.

Three letters to the editors and the response by my FAU Erlangen-Nbg colleagues regarding CAR T-cell therapy in autoimmune disease NEJM
nejm.org/doi/10.1056/NE…

T-DXd is highly active for HER2-mutant NSCLC. Could it work also in other tumors with HER2-mutations? In DESTINY-PT01, 102 pts with solid tumors harboring activating HER2 mutations received T-DXd. ORR 29%, PFS 5.4 months. Highest activity in breast cancer. thelancet.com/journals/lanon…

Really interesting article by Niklas Klümper in EJC 🤓🤓

Post-hoc analyses from the IMvigor211 and IMmotion151 💉💉

A simple and cheap predictor of IO efficacy >Blood sodium levels 🧂🧂

Could be very practical and beneficial for the patients 🤞🤞

A great discussion on the…

We are happy to share our new study published today Journal of Clinical Oncology (👉 ascopubs.org/doi/10.1200/JC…) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer.
With a huge contribution of our multinational team we uncovered…

🚨New Paper Alert! 🚨Targeting NECTIN4. Predicting Response to Enfortumab Vedotin in Metastatic Urothelial Cancer
Journal of Clinical Oncology Niklas Klümper Markus Eckstein Michael Hölzel Viktor Grünwald Joshua Meeks Christoph Kuppe Else Kröner-Fresenius-Stiftung

Summary by Amalya Sargsyan
oncodaily.com/58904.html

Very important study from a team led by Markus Eckstein Niklas Klümper highlighting NECTIN4 amplification as a potential predictive biomarker for treatment with EV in #BladderCancer patients Petros Grivas Amanda Nizam, MD Uromigos IBCG Bladder Cancer Advocacy Network

Thanks Vadim Koshkin MD for picking it up ! 😊

Interesting work from Niklas Klümper et al —Na levels may module ICB response. Still so much unknown in this area. Congrats for the elegant work Niklas!

Fantastic work on molecular subtypes Cancer Cell paper & awesome commentary Chadi Hage Chehade Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute UroToday.com Kidney Cancer KidneyCAN Toni Choueiri, MD Chris Labaki Bradley McGregor Brian Rini, MD Laurence Albiges Talal El Zarif, MD Uromigos Sumanta K. Pal, MD, FASCO Robert Motzer MD Tom Powles OncoAlert

Happy to share our editorial recently published in Cancer Cell ! Grateful for terrific mentorship from Neeraj Agarwal, MD, FASCO and team Umang Swami Benjamin L Maughan Georges Gebrael GU Cancer Research Program @HuntsmanCancer 👉tinyurl.com/48px5rw8👇👇

💉🩸High serum sodium predicts response to IO in mUC and mRCC
EORTC Oncology Advance

➡️Posthoc analyses of IMvigor211 (mUC, atezolizumab) and IMmotion151 (mRCC, atezolizumab+bevacizumab) trials
✅Baseline serum sodium levels of >140mmol/L : higher objective response⬆️
✅Serum…

We are happy to share our current manuscript: In an exploratory post-hoc analysis of IMmotion151 (mRCC, atezo + beva) and IMvigor211 (mUC, atezo), in which we correlated baseline electrolyte concentration with ICB response and outcome in an unbiased manner, we made an interesting…

Niklas Klümper Journal of Clinical Oncology Great work and looking forward to more data in the future- the big question is whether patients without amplification or overexpression do better with other treatments than with EV- this requires biomarker directed prospective trials to answer this question.

Really excited to see the results Paolo Tarantino !!!!

Great work by Niklas Klümper et al. finding that 24% of mUC have Nectin4 ampl, which predicts ⬆️ORR (96% vs 32%) & ⬆️OS with the ADC #EV . Excited to see EV data for MBC presented at ASCO by Antonio Giordano, MD PhD & to study this biomarker in breast cancer. Congrats! ascopubs.org/doi/full/10.12…

Honored to share our most recent work, where we leveraged bispecific T cell engagers to treat refractory rheumatoid arthritis 💥

Happy to share a collaborative work where I was involved as „immunopathologist“ Nature Medicine ! Beside my oncology hobby we provide services for tissue monitoring therapy responses to autoimmune diseases.
Led by Ricardo Grieshaber-Bouyer and Georg Schett our study shows
👉 that…

Congratulations 👏👏👏

With the rise of antibody-drug conjugates, precise biomarker identification is key to revolutionizing care. #CancerResearch #PersonalizedMedicine #ClinicalOncology 🧬💊🔬

🚨 Does TP53 status overshadows the prognostic significance of HPV in penile cancer patients?

❗️Read all about it in the first single-cell RNA sequencing atlas of penile cancer: authors.elsevier.com/a/1i%7Elg14kpl…
European Urology

Let’s go on a biological journey through this paper:🧵(1/9)